Invesco Biotechnology & Genome ETF
PBE
68 hedge funds and large institutions have $56.9M invested in Invesco Biotechnology & Genome ETF in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 7 closing their positions.
12% more capital invested
Capital invested by funds: $51M → $56.9M (+$5.9M)
0.5% more ownership
Funds ownership: 20.82% → 21.33% (+0.5%)
7% less funds holding
Funds holding: 73 → 68 (-5)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
SignalPoint Asset Management
Springfield,
Missouri
|
+$2.83M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.67M |
| 3 |
Morgan Stanley
New York
|
+$887K |
| 4 |
SG Americas Securities
New York
|
+$816K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$468K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$3.4M |
| 2 |
CWM
Concert Wealth Management
San Jose,
California
|
-$1.13M |
| 3 |
TAM
Trillium Asset Management
Boston,
Massachusetts
|
-$819K |
| 4 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
-$625K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$560K |
PBE Hedge Fund Activity: Q3 2016 in Review
68 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2016, worth a combined $56.9M — up 12% from $51M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PBE and 4 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 19 added.
The largest buyer was SignalPoint Asset Management, adding an estimated $2.83M. The largest seller was Bank of America, cutting an estimated $3.4M.
- 68 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2016, down from 73 in Q2 2016.
- Funds reported $56.9M of Invesco Biotechnology & Genome ETF stock for Q3 2016, up 12% quarter-over-quarter.
- 4 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2016 and 7 closed out, a net change of -3 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q3 2016 was SignalPoint Asset Management, an estimated $2.83M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q3 2016 was Bank of America, an estimated $3.4M sold.
Based on aggregated 13F filings for Q3 2016.